Hematology (all articles)
WHO recommends against the use of convalescent plasma to treat COVID-19.
8 Dec, 2021 | 10:24h | UTCNews Release: WHO recommends against the use of convalescent plasma to treat COVID-19 – World Health Organization
See Guidance: WHO’s living guidelines on COVID-19 therapeutics
Infographic: A living WHO guideline on drugs for covid-19 – The BMJ
Commentary on Twitter (thread – click for more)
Convalescent plasma is a transfusion of blood plasma from someone who has recovered from #COVID19, and is used as a treatment for COVID19 https://t.co/Bobq7OTDGq pic.twitter.com/pfO1sFvUpJ
— World Health Organization (WHO) (@WHO) December 7, 2021
ESC Position Paper: Optimal follow-up after acute pulmonary embolism.
8 Dec, 2021 | 10:02h | UTC
Commentary on Twitter
Do you routinely discuss how/when to resume sporting activities and traveling with your PE patients? Or future cardiovascular risk? Check this recent ESC/ERS position paper on optimal follow-up of acute PE for these and other key aspects of counselling: https://t.co/KEQ7FnFwXX
— Erik Klok (@Erik_Klok_MD) December 7, 2021
RCT: Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant.
7 Dec, 2021 | 08:37h | UTC
Another randomized trial showed convalescent plasma does not benefit patients hospitalized with Covid-19.
1 Dec, 2021 | 09:49h | UTCRelated:
M-A: Convalescent plasma does not reduce mortality in COVID-19.
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Commentary on Twitter
The TSUNAMI RCT showed that high-titer convalescent plasma (CP) did not reduce the risk of severe respiratory failure or death in hospitalized patients with #COVID19 pneumonia. https://t.co/4q0S2AtfMj
— JAMA Network Open (@JAMANetworkOpen) November 29, 2021
Review: Castleman disease.
26 Nov, 2021 | 09:49h | UTCCastleman disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Castleman Disease (if the link is paywalled, try this one)
Review: Prevention and management of thrombosis in hospitalized patients with COVID-19 pneumonia.
26 Nov, 2021 | 08:44h | UTC
Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children.
25 Nov, 2021 | 10:31h | UTC
A prospective cohort study showed a 3.1% risk for recurrent venous thromboembolism at 90 days in patients with subsegmental pulmonary embolism managed without anticoagulation.
24 Nov, 2021 | 08:31h | UTCRisk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
First prospective study including patients with isolated SSPE managed without anticoagulation published in @AnnalsofIM. Rate of recurrent VTE is 3.1% . Nice collaboration between @INNOVTE1 and @canvector funded by @HeartandStroke https://t.co/GdcbM1fRp1 @OttMethodsCentr
— Marc Carrier (@MarcCarrier1) November 23, 2021
M-A: Convalescent plasma does not reduce mortality in COVID-19.
21 Nov, 2021 | 23:09h | UTCRelated:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
M-A: Intravenous iron is associated with increased risk of infection when compared with oral iron or no iron, which must be balanced with the potential benefits of reducing blood transfusion requirements.
19 Nov, 2021 | 10:31h | UTCInvited Commentary: Intravenous Iron and Infection Risk—Still an Unanswered Question – JAMA Network Open
Commentary on Twitter
In this systematic review and meta-analysis, administration of intravenous iron was associated with an increased risk of infection. This risk must be balanced with the potential benefits of treating anemia and reducing blood transfusion requirements. https://t.co/XkNJKCk7M7
— JAMA Network Open (@JAMANetworkOpen) November 12, 2021
Novel gene therapy for hemophilia A leads to sustained expression of clotting factor and reduced bleeding events.
19 Nov, 2021 | 10:25h | UTCOriginal Study: Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A – New England Journal of Medicine
Commentary on Twitter
3.5 years after therapy with factor VIII-containing adeno-associated virus, 16 of 18 men with hemophilia A had enough factor VIII expression that bleeding events were reduced to nearly zero and prophylaxis was discontinued. https://t.co/n3cPyjGDkn pic.twitter.com/vPyz0OmT1S
— NEJM (@NEJM) November 18, 2021
Review: Vaccine-induced immune thrombotic thrombocytopenia.
16 Nov, 2021 | 08:46h | UTCVaccine-induced immune thrombotic thrombocytopenia – The Lancet Haematology
Related:
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)
Commentary on Twitter
NEW Viewpoint by @Erik_Klok_MD, @MPaiMD, Menno Huisman & @ProfMakris discussing the epidemiology, pathophysiology, and optimal diagnostic and therapeutic management of vaccine-induced immune thrombotic thrombocytopenia #VITT #COVID19Vaccine https://t.co/FI4NynwzEn pic.twitter.com/9PbjaioA2T
— The Lancet Haematology (@TheLancetHaem) November 12, 2021
#AHA21 – [Not published Yet] A small, randomized study showed stopping ticagrelor only 2-3 days before bypass surgery may be safe.
14 Nov, 2021 | 19:56h | UTCCommentary: RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor – TCTMD
Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia.
14 Nov, 2021 | 19:32h | UTCNews release: Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy – NIH News Releases
Commentary on Twitter
Clinical trial showed that pediatric patients with acute promyelocytic leukemia (APL) have very high cure rates with treatment regimen that uses targeted therapy and no cytotoxic chemotherapy for standard risk APL or limited anthracycline for high risk APL https://t.co/V3mahhIb6Y
— JAMA Oncology (@JAMAOnc) November 11, 2021
RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.
7 Nov, 2021 | 20:18h | UTCDaprodustat for the Treatment of Anemia in Patients Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this phase 3 clinical trial, daprodustat was effective as a treatment for anemia in patients with CKD who were undergoing maintenance hemodialysis or peritoneal dialysis. #KidneyWk https://t.co/ykzSsUlJci pic.twitter.com/0zdlMyOlTf
— NEJM (@NEJM) November 5, 2021
RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.
7 Nov, 2021 | 20:17h | UTCDaprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial, daprodustat was as effective as darbepoetin alfa in increasing and maintaining hemoglobin levels in patients with CKD and anemia who were not receiving dialysis. #KidneyWk https://t.co/D2unQFLH6T pic.twitter.com/KqdLfVlkuD
— NEJM (@NEJM) November 5, 2021
Cluster RCT: In older adults with advanced cancer, a geriatric assessment program reduced the toxic effects of cancer treatment.
5 Nov, 2021 | 09:48h | UTCRelated:
Perspective: A Cancer Care Approach Tailored to The Elderly May Have Better Results
Commentary from the author on Twitter (thread – click for more)
https://twitter.com/rochgerionc/status/1456046017766375425
CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.
4 Nov, 2021 | 10:06h | UTCCommentaries:
Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN
Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News
ASH Guideline issued a conditional recommendation against routine use of outpatient anticoagulant prophylaxis in patients with COVID-19 being discharged from the hospital.
4 Nov, 2021 | 10:03h | UTC
ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
2 Nov, 2021 | 02:51h | UTC
ASCO Guideline: Management of immune-related adverse events in patients treated with Chimeric Antigen Receptor T-Cell Therapy.
2 Nov, 2021 | 02:47h | UTC
RCT: Daratumumab, lenalidomide, and dexamethasone vs. lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma.
28 Oct, 2021 | 09:53h | UTC
Anticoagulants and diabetes agents are among the most frequent causes of emergency department visits attributed to medication harms.
27 Oct, 2021 | 01:15h | UTCUS Emergency Department Visits Attributed to Medication Harms, 2017-2019 – JAMA (link to abstract – $ for full-text)
Commentaries:
Number of emergency room visits for medication harms increases with age – MedicalResearch.com
Blood thinners, diabetes meds among top causes of drug-related ER visits – UPI
Guideline: Transfusion strategies in bleeding critically ill adults.
24 Oct, 2021 | 23:47h | UTC
Commentary on Twitter
Transfusion strategies in bleeding critically ill adults current evidence/research areas from @ESICM clinical practice guideline
🩸massive bleedings
🩸non‑massive bleedings
🩸tranexamic acid in traumatic/non‑traumatic hemorrhages
Open #FOAMcc on @yourICM
🖇️https://t.co/LtEzrLcaM5 pic.twitter.com/Po7eFYpdeW— Intensive Care Medicine (@yourICM) October 22, 2021
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
21 Oct, 2021 | 10:06h | UTCRelated:
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.